Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR-ONC-13003949Phase 2Completed
Phase 2, open-label, single-arm trial of irinotecan and capecitabine in gastric adenocarcinoma, sponsored by Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Primary endpoint: Progression-free survival. Started Sep 2014; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR-ONC-13003949.